Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"If there's a statistically discernible and beneficial distinction between the treatment and placebo group with regard to long-haul morbidity (presuming the treatment group shows a lower incidence of symptoms), it would be a significant data point."

No doubt. And they should be able to get some reasonably meaningful, if not perfect, data with a phone poll. At least an inkling.

But anything other than morbidity and the self-reporting over the phone stuff gets statistically less reliable.


3. Follow-up period (Day 4-6 through Day 60): Subjects will be assessed daily while hospitalized. Discharged patients will be asked to attend study visits at Days 15 and 29. A follow-up visit at Day 60(±10), by telephone call, is also included to confirm patient status.
10. Incidence of treatment-emergent adverse events [ Time Frame: Day 1 through Day 60 ]
Treatment-emergent Adverse Events (TEAEs) have onset dates on or after the study treatment start date